X0609 4 2026-08-21 0001628171 Revolution Medicines, Inc. RVMD 0001969082 Cislini Jeff false C/O REVOLUTION MEDICINES, INC. 700 SAGINAW DRIVE REDWOOD CITY CA 94063 false true false false General Counsel true Common Stock 2026-08-21 4 M false 29680 18.56 A 86201 D Common Stock 2026-08-21 4 M false 26600 21.61 A 112801 D Common Stock 2026-08-21 4 S false 3400 207.2363 D 109401 D Common Stock 2026-08-21 4 S false 17323 208.3688 D 92078 D Common Stock 2026-08-21 4 S false 25817 209.2497 D 66261 D Common Stock 2026-08-21 4 S false 2540 210.2647 D 63721 D Common Stock 2026-08-21 4 S false 4500 211.3417 D 59221 D Common Stock 2026-08-21 4 S false 3314 212.0583 D 55907 D Stock Option (Right to Buy) 18.56 2026-08-21 4 M false 29680 0 D 2026-03-01 2032-02-29 Common Stock 29680 0 D Stock Option (Right to Buy) 21.61 2026-08-21 4 M false 26600 0 D 2032-08-31 Common Stock 26600 3500 D Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on May 22, 2026. Includes 43,514 restricted stock units. This transaction was executed in multiple trades in prices ranging from $206.76 to $207.75, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. This transaction was executed in multiple trades in prices ranging from $207.765 to $208.75, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. This transaction was executed in multiple trades in prices ranging from $208.77 to $209.61, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. This transaction was executed in multiple trades in prices ranging from $209.77 to $210.72, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. This transaction was executed in multiple trades in prices ranging from $210.77 to $211.76, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. This transaction was executed in multiple trades in prices ranging from $211.77 to $212.74, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from September 1, 2022 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. /s/ Jack Anders, as Attorney-in-fact for Jeff Cislini 2026-08-25